Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 19, 2016

AMGEN INC.

(Exact name of registrant as specified in its charter)

 

Delaware    001-37702            95-3540776

(State or other jurisdiction of

incorporation)

   (Commission File Number)           

(IRS Employer

Identification No.)

 

One Amgen Center Drive

Thousand Oaks, California

   91320-1799
(Address of principal executive offices)    (Zip Code)

805-447-1000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07.  Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting on May 19, 2016. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:

Item 1 - Election of Directors

Each of the following 13 nominees for director were elected to serve a one-year term expiring at the Company’s 2017 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.

 

Name      Votes For      Votes Against      Abstain     

Broker Non-

Votes

Dr. David Baltimore      572,667,041      11,816,532         873,734      82,748,533
Mr. Frank J. Biondi, Jr.      570,371,594      14,049,140         936,573      82,748,533
Mr. Robert A. Bradway      555,016,175      24,586,112      5,755,021      82,748,533
Mr. François de Carbonnel      579,902,691        3,061,399      2,393,217      82,748,533
Mr. Robert A. Eckert      581,028,352        3,375,561         953,394      82,748,533
Mr. Greg C. Garland      571,930,824      12,467,261         959,222      82,748,533
Mr. Fred Hassan      578,198,604        6,204,974         953,730      82,748,533
Dr. Rebecca M. Henderson      580,191,699        2,899,140      2,266,468      82,748,533
Mr. Frank C. Herringer      576,630,107        7,795,152         932,048      82,748,533
Dr. Tyler Jacks      580,074,899        4,376,060         906,348      82,748,533
Ms. Judith C. Pelham      574,790,440        9,751,026         815,841      82,748,533
Dr. Ronald D. Sugar      575,822,411        8,639,800         895,096      82,748,533
Dr. R. Sanders Williams      580,055,013        4,428,538         873,757      82,748,533

Item 2 - Ratification of Selection of Independent Registered Public Accountants

Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2016. No Broker Non-Votes resulted from the vote on this proposal.

 

For:   657,695,146
Against:   8,974,699
Abstain:   1,435,996

Item 3 - Advisory Vote to Approve Our Executive Compensation

The advisory vote to approve our executive compensation was approved.

 

For:   565,511,840
Against:   17,766,367
Abstain:   2,079,101
Broker Non-Votes:   82,748,533

 

1


Item 4 – Stockholder Proposal

The stockholder proposal to change the voting standard applicable to non-binding proposals submitted by stockholders was not approved.

 

For:   38,258,319
Against:   543,777,178
Abstain:   3,321,811
Broker Non-Votes:   82,748,533

No other matters were submitted for stockholder action.

A copy of the press release announcing the vote results is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

Item 9.01        Financial Statements and Exhibits.

(d) Exhibits

99.1    Press Release, dated May 19, 2016

 

2


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   AMGEN INC.
Date: May 19, 2016      
   By:   

  /s/  Jonathan P. Graham

   Name:    Jonathan P. Graham
   Title:    Senior Vice President, General Counsel and Secretary

 


EXHIBIT INDEX

 

Exhibit

No.

    

Document Description

99.1      Press Release, dated May 19, 2016